Dr. Charles Bugg, Chairman and CEO of BioCryst Pharmaceuticals, Inc.,
Rings The NASDAQ Stock Market Opening Bell

Tuesday, August 22, 2006
at NASDAQ's MarketSite
in New York City.

BioCryst Pharmaceuticals, Inc.

Dr. Charles Bugg, Chairman and CEO of BioCryst Pharmaceuticals, Inc. (BCRX), presides over the opening bell to celebrate its 20th-business anniversary.

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(tm) in oncology, BCX-4208 in transplantation and autoimmune diseases, peramivir in seasonal and life-threatening influenza, and BCX-4678 in hepatitis C. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208 and is collaborating with Mundipharma Holdings for the development and commercialization of Fodosine(tm) in markets across Europe, Asia, Australia and certain neighboring countries. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 8/22/2006 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Dr. Charles Bugg, Chairman and CEO of BioCryst Pharmaceuticals, Inc. (BCRX), rings the Opening Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.